The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes.
about
Diabetes DyslipidemiaThe Role of Metformin Response in Lipid Metabolism in Patients with Recent-Onset Type 2 Diabetes: HbA1c Level as a Criterion for Designating Patients as Responders or Nonresponders to MetforminAVE8134, a novel potent PPARα agonist, improves lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats.Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetesIs the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysisDiabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapiesPioglitazone and sulfonylureas: effectively treating type 2 diabetesTreating insulin resistance in type 2 diabetes with metformin and thiazolidinediones.PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.Cardiovascular disease prevention in patients with type 2 diabetes: The role of oral anti-diabetic agents.Oral antidiabetic agents as cardiovascular drugs.Combining insulins with oral antidiabetic agents: effect on hyperglycemic control, markers of cardiovascular risk and disease.Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies.Effects of Three Medicinal Plants Extracts in Experimental Diabetes: Antioxidant Enzymes Activities and Plasma Lipids Profiles inComparison with Metformin.Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity or mortality? No.On the potential of acarbose to reduce cardiovascular disease.Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes.Overview of metformin: special focus on metformin extended release.Individualized treatment of type 2 diabetes mellitus using noninsulin agents: clinical considerations for the primary care physician.Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.Lipid effects and cardiovascular disease risk associated with glucose-lowering medications.Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review.Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes.PHYSIOLOGY AND ENDOCRINOLOGY SYMPOSIUM: Insulin action and lipotoxicity in the development of polycystic ovary syndrome: A review.Cross-Talk between PPARgamma and Insulin Signaling and Modulation of Insulin Sensitivity.Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins.Fixed combination of repaglinide and metformin in the management of type 2 diabetes.Differential effects of pioglitazone on metabolic parameters in newly diagnosed, drug-naïve Japanese patients with type 2 diabetes with or without metabolic syndrome.Interaction of barley β-glucan and tea polyphenols on glucose metabolism in streptozotocin-induced diabetic rats.The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin-resistant subjects.Non-estrogenic Xanthohumol Derivatives Mitigate Insulin Resistance and Cognitive Impairment in High-Fat Diet-induced Obese Mice.Bio-extract-mediated ZnO nanoparticles: microwave-assisted synthesis, characterization and antidiabetic activity evaluation.Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions.Factors That Influence Pancreatic Beta Cell Function and Insulin Resistance in Newly Diagnosed Type 2 Diabetes Patients: A Sub-Analysis of the MARCH Trial.Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy.Beneficial metabolic effects of nateglinide versus acarbose in patients with newly-diagnosed type 2 diabetes.Effect of metformin monotherapy on serum lipid profile in statin-naïve individuals with newly diagnosed type 2 diabetes mellitus: a cohort study.Role of Lipotoxicity and Contribution of the Renin-Angiotensin System in the Development of Polycystic Ovary Syndrome.
P2860
Q26750905-021E5BC8-B6CB-443F-ABDC-B7E81D2D6ADEQ28550746-6B0930C1-1D39-4B96-9D20-D04589578E14Q33567011-B81EC253-062F-4557-A80A-06D95820DCACQ33797616-0AAF72C8-4EAC-46F6-94B8-295E1D2CD332Q33880174-A4C184DB-8CA1-49B8-9BFD-0469995E8117Q33949425-A5EA64BF-ABC2-4D59-AB31-64A88DE15176Q35987456-F0D8E42B-0CCB-4FA6-B8DD-9A6D09263114Q36283822-89917DE7-5B51-4D7A-B4B9-75459501C78EQ36536316-5C14C06C-4C2A-413C-B425-827B5B64547BQ36679594-E47006AD-67E2-4086-8BEC-07B16D6D4BD8Q36697741-02D0CDFE-8536-48C8-BF57-7B02177EFC0AQ36835841-FF9B3287-28DC-4988-86F4-96FA6E35F4A2Q36844378-6C81B783-46C0-4BF1-BC24-DD12826ED21AQ37268233-76DBE628-EB3E-40A2-87D3-421C39F20122Q37624301-E7A22D77-23DB-44A9-A337-92E58970FAB2Q37717838-4B55A3B8-5C77-41A1-89AE-F4DE91B9F1A2Q37875220-495B1EAD-2661-4222-9303-32A3087A5C46Q38024861-144FB3DA-E11D-4F41-8A14-45F8DA2E0935Q38036773-A603EA24-191D-4DE3-9A95-8D815F8D35ABQ38038097-B1FA9282-6564-45E1-A8BA-38D18991B4DFQ38511039-9FAA0D23-413D-4075-9450-A6BE4BB93AFCQ38563239-F0519CFB-0E18-4D4F-82DA-630E60AA82CFQ38783203-9320A631-00C1-49C0-BFC6-85943ECEEBEBQ38861206-E0B58716-F11C-4827-A921-7433D29006F0Q39209941-654985DC-0AE7-407F-8D50-BBDA1EF984BEQ39320400-DDFC2780-3A7F-4136-8742-6E7BB56E287FQ42178891-FDD9E563-D7A9-4C74-BEE9-3459715D83EEQ42936496-F7FF1DE3-59EF-45CC-9F80-CE34AF3B1C5BQ44000340-DFAFB02F-FD7B-40A6-B0F6-D067893107C0Q46545835-8459156F-E130-4528-94FA-0AFD93191703Q47657818-60BC3D7C-EED3-4040-98A8-E34D437228AEQ48004109-6AFE683F-72DF-46E4-BB53-DF8106BD3BDFQ49689988-2BDF1F4E-39BB-4769-AF98-CEFE656A727DQ51245631-D1F138D2-5170-48B9-8D10-CEA254AEB06EQ51468997-516D314D-2260-4CAD-9145-5EDC21D4E5F0Q51475245-1AD9EEF9-BB39-417D-8DC9-21A98CB95ADFQ55314889-6B8509BA-5392-4433-9086-8C2A1AB0BEABQ55403020-9E57339E-68E6-4E43-B544-E0B71F5ACCD1
P2860
The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The effects of oral anti-hyper ...... patients with type 2 diabetes.
@ast
The effects of oral anti-hyper ...... patients with type 2 diabetes.
@en
type
label
The effects of oral anti-hyper ...... patients with type 2 diabetes.
@ast
The effects of oral anti-hyper ...... patients with type 2 diabetes.
@en
prefLabel
The effects of oral anti-hyper ...... patients with type 2 diabetes.
@ast
The effects of oral anti-hyper ...... patients with type 2 diabetes.
@en
P2093
P2860
P1476
The effects of oral anti-hyper ...... patients with type 2 diabetes
@en
P2093
P2860
P304
P356
10.1111/J.1462-8902.2004.00325.X
P50
P577
2004-03-01T00:00:00Z